The following guidance has been issued to set out the HTA’s expectations regarding the use of alternative reagents and materials during the processing of tissues and cells in the event there is a supply disruption to critical reagents and materials as a result of the UK exiting the EU.
HTA licensed establishments in the Post-mortem sector are required to report incidents to the HTA - we call these HTARIs - and those in the Human Application and Organ Donation and Transplantation sectors are required to report serious adverse events or reactions (SAEARs), as part of their licensing requirements.
In line with the HTA's commitment to transparency, we will be publishing reports every quarter detailing the volume and nature of incidents reported.
Under the Enterprise Act 2016, the HTA and all other statutory regulators have a duty to report against the Government’s Business Impact Target. The target for the 2015-2020 Parliament is a £10 billion reduction in the cost of regulation to business.
The objectives of the BIT are to:
The Government has set out the need for greater transparency to enable the public to hold public bodies and politicians to account. This includes commitments relating to public expenditure, intended to help reduce the deficit and achieve better value for money.
You can browse and read previous FOI responses below.
For FOI responses before 2018, please see the national archive website.
The HTA has a responsibility to make its information available in accordance with the Freedom of Information Act. Before making a Freedom of Information request please take the time to check that it is not already available on one of these pages:
The duties of the Remuneration Committee are to:
The Authority – the HTA’s non-executive board – is made up of a Chair and 11 Members who are appointed by the Secretary of State for Health, with the exception of one Member appointed by the Welsh Minister and one by the Minister in Northern Ireland.
